About CranioVation
CranioVation is a company based in Rochester (United States) founded in 2017 was acquired by Springfield in May 2018. CranioVation has raised $7.61 million across 6 funding rounds from investors including Springfield Properties. CranioVation operates in a competitive market with competitors including PhotoPharmics, Lumeda, Adgero Biopharma, SpectraCure and Photolitec, among others.
- Headquarter Rochester, United States
- SectorsHealthcareTechnology
- Email••••••••
- Website craniovation.com
- Social X
- Acquired by Springfield (May 2018)
- Total Equity Funding$7.61M (USD)
in 6 rounds
- Latest Funding Round$6M (USD), Series A
Dec 2020
- Investors
- Acquired bySpringfield
(May 2018)
Funding Insights of CranioVation
CranioVation has successfully raised a total of $7.61M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $6 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.61M
- Total Rounds 6
- Last Round Series A — $6M
- First Round $225,000
(Sep 2017)
All 6 funding rounds of CranioVation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $6M | Series A | – | – | – |
| May 2020 | $519,000 | Debt – Conventional | – | – | – |
| May 2018 | $1.28M | Seed | – | – | – |
| Mar 2018 | $150,000 | Debt – Conventional | – | – | – |
| Jan 2018 | $100,000 | Seed | – | – | – |
| Sep 2017 | $225,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in CranioVation
CranioVation has secured backing from 1 investor. Prominent investors backing the company include Springfield Properties.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Springfield Properties is engaged in building new homes in Scotland. | 1956 | springfield.co.uk | Elgin, United Kingdom |
Investor details for CranioVation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CranioVation
3 people are tracked at CranioVation (3 in leadership).
| Name | Role | Group |
|---|---|---|
Braden Eliason | Chief Technology Officer | Leadership |
Vijay Agarwal | Founder & CEO | Leadership |
Steve Weiner | Chief Financial Officer | Leadership |
Complete people profiles for CranioVation
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CranioVation
4 dated milestones of CranioVation across 3 years, from founding to its latest funding, stage changes and deals.
- Founded CranioVation is founded.
- Funding First funding round of $225K.
- Exit Acquired by Springfield.
- Funding Latest funding round, Series A, of $6.0M.
Competitors of CranioVation
CranioVation operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, Lumeda, Adgero Biopharma, SpectraCure and Photolitec, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| lumedainc.com | 2020 | Rocky Hill, United States | $5.34M | 10 | Photodynamic therapy device for lung cancer treatment is developed. | |
| adgerobiopharm.com | 2012 | Princeton, United States | $5.52M | – | Photodynamic therapy for cutaneous metastatic breast cancer is developed. | |
| spectracure.com | 2003 | Lund, Sweden | – | – | Developer of Interstitial photo dynamic therapy for solid tumours | |
| photolitec.org | 2010 | Buffalo, United States | $5M | – | Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. | |
| illumimedical.com | 2023 | Nagoya, Japan | $2.26M | – | Photodynamic therapy devices for cancer treatment are developed. | |
| impactbiotech.com | 2022 | Ness Ziona, Israel | – | – | Developer of a drug delivery platform for the treatment of solid tumors | |
| illumacell.com | 2008 | Waterloo, Canada | – | – | Provider of medical light technology for photodynamic therapy cancer treatment |
Detailed competitors of CranioVation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to CranioVation
10 companies that operate in the same segment as CranioVation (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CranioVation
CranioVation was founded in 2017.
CranioVation is headquartered in Rochester, United States.
CranioVation is a funded company, having raised a total of $7.61M across 6 funding rounds to date. The company's 1st funding round was a Seed of $225K, raised on Sep 2017.
CranioVation was founded in 2017 and is located in Rochester, United States. Devices for the minimally invasive treatment of brain tumors are supplied by the company within the medical devices sector. Photodynamic therapy is employed, where light activates photosensitizers to target and eliminate cancer cells. Deeply located tumors can be addressed through brief procedures, typically a few minutes long, conducted while patients are awake. Operations emphasize neuro-oncological applications.
CranioVation's top competitors include PhotoPharmics, ImPact Biotech and Adgero Biopharma.
CranioVation has 1 investor. Key investors include Springfield Properties.
Yes. CranioVation was acquired by Springfield in May 2018.